MARKET

TXMD

TXMD

TherapeuticsMD
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.550
-0.020
-1.27%
After Hours: 1.560 +0.01 +0.65% 17:51 08/11 EDT
OPEN
1.590
PREV CLOSE
1.570
HIGH
1.650
LOW
1.550
VOLUME
3.47M
TURNOVER
--
52 WEEK HIGH
4.320
52 WEEK LOW
0.8530
MARKET CAP
421.11M
P/E (TTM)
-2.1474
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TXMD stock price target is 6.91 with a high estimate of 13.00 and a low estimate of 1.250.

EPS

TXMD News

More
TherapeuticsMD, Inc. (TXMD) CEO Robert Finizio on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 3d ago
TherapeuticsMD® Announces Second Quarter 2020 Financial Results
TXMD discusses business and financial results for Q2 2020 on earnings conference call today at 8:30 a.m.
Business Wire · 5d ago
TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:34
TherapeuticsMD to Report Second Quarter 2020 Results on August 6, 2020
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its second quarter 2020 financial results on Thursday, August 6, 2020, before the opening of the U.S. financial markets. Following the announceme
Business Wire · 07/29 10:50
Will TherapeuticsMD (TXMD) Report Negative Q2 Earnings? What You Should Know
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 16:33
TherapeuticsMD expands access to Annovera
TherapeuticsMD (NASDAQ:TXMD) to expand access to Annovera (segesterone acetate and ethinyl estradiol vaginal system), an annual birth control ring via the
seekingalpha · 07/15 16:43
TherapeuticsMD And Nurx Expand Access To ANNOVERA
Largest online practice for women’s health now offers the first FDA-approved long-lasting birth control method that does not require a medical procedure BOCA RATON, Fla. & SAN FRANCISCO--(BUSINESS WIRE)--
Benzinga · 07/15 10:50
When Will TherapeuticsMD, Inc. (NASDAQ:TXMD) Breakeven?
Simply Wall St. · 06/28 14:41

Industry

Pharmaceuticals
-0.41%
Pharmaceuticals & Medical Research
-0.93%

Hot Stocks

Symbol
Price
%Change

About TXMD

TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.
More

Webull offers kinds of TherapeuticsMD Inc stock information, including NASDAQ:TXMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TXMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TXMD stock methods without spending real money on the virtual paper trading platform.